Electrophysiologic effects and efficacy of recainam for sustained ventricular tachycardia.

was effective for controlling 64% of patients, with partial control achieved in an additional 13%. The incidence of side effects necessitating drug withdrawal was 15%. In the study of Hammill et al, most patients (60%) had no significant cardiovascular disease, while 74% of Kerr’s group had primary AF without associated heart disease. We had a lower success rate than these 2 previous groups, but our patient population all had underlying heart disease and chronic AF. The arrhythmia may have been more difficult to control due to these 2 vaiiables. cardia. Am J Cardiol 1983;S2:1208ml 213. 2. Podrid PJ, Lown BL. Propafenone: a new agent for ventricular arrhythmia. JACC 1984:4:117-l 25. 3. Dinh Ha, Baker BJ, De Soyza N, Murphy ML. Sustained therapeutic efficacy and safety of oral propafenone for treatment of chronic ventricula;arrhythmia: a 2-year experience. Am Heart J 1988;115:92-96. 4. Manz M, Steinbeck G, Luderitz B. Usefulness of programmed stimulation in predicting efficacy of propafenone in long-term antiarrhythmic therapy for paroxysmal supraventricular tachycardia. Am J Cardiol 1985;56:595-597. 5. Hammill SC, McLaran CJ, Wood DL, Osborn MJ, Gash BJ, Holmes DR. Double-blind study of intravenous propafenone for paroxysmal supraventricular reentrant tachycardia. JACC 1987:9:1364-1368. 6. Hammill SC, Wood DL, Gersh BJ, Osborn MJ, Holmes DR. Propafenone for paroxysmal atrial fibrillation. Am J Cardiol 1988;61:473-474. 7. Kerr CR, Klein GJ, Axelson JE, Cooper JC. Propafenone for prevention of recurrent atria1 fibrillation. Am J Cardiol 1988,61:914-916. 6. Ledda F, Mantelli L, Manzini S, Amerini S, Mugelli A. Electrophysiological 1. Connolly SJ, Kates RE, Lebsack CS, Echt DS, Mason JW, Winkle RA. and antiarrhythmic properties of propafenone in isolated cardiac preparations. J Clinical efficacy and electrophysiology of oral propafenone for ventricular tachyCardiouasc Pharmacol 1981;3:1162ml 173.